Why Collegium Pharmaceutical Shares Are Tumbling 12.9% Today Wed, 22 Nov 2017 21:18:00 +0000 The FDA is working on ways to encourage the development of abuse-deterrent opioid pain relievers, and that's potentially bad news for this tiny biotech.
Collegium to Present at the 29th Annual Piper Jaffray Healthcare Conference Wed, 22 Nov 2017 13:42:34 +0000 CANTON, Mass., Nov. 22, 2017-- Collegium Pharmaceutical, Inc. today announced that senior management will participate in a fireside chat at the 29 th Annual Piper Jaffray Healthcare Conference at 2:30pm ...
Collegium Pharmaceutical, Inc. – Value Analysis (NASDAQ:COLL) : November 13, 2017 Mon, 13 Nov 2017 18:56:57 +0000 Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Collegium Pharmaceutical, Inc. a score of 29. Our analysis is based on comparing Collegium Pharmaceutical, Inc. with the following peers – Aoxing Pharmaceutical Company, Inc., Horizon Pharma plc, Agile Therapeutics, Inc. and Apricus Biosciences, Inc. (AOXG-US, HZNP-US, AGRX-US and APRI-US). Investment Outlook Collegium Pharmaceutical, Inc. has a ... Read more
(Read more...)
Collegium Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : COLL-US : November 10, 2017 Fri, 10 Nov 2017 12:17:34 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Collegium Pharmaceutical, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more
(Read more...)
Collegium Pharmaceutical posts 3Q loss Wed, 08 Nov 2017 22:25:36 +0000 On a per-share basis, the Canton, Massachusetts-based company said it had a loss of 45 cents. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
Collegium Reports Third Quarter Financial Results and Provides Corporate Update Wed, 08 Nov 2017 21:01:00 +0000 Xtampza ® ER prescriptions grow by 49% in the third quarter FDA Approval of sNDA, including Comparative OxyContin Data Strong balance sheet provides cash runway into mid-2019 Conference call scheduled ...
Neos Therapeutics reports 3Q loss Wed, 08 Nov 2017 14:54:31 +0000 On a per-share basis, the Grand Prairie, Texas-based company said it had a loss of 58 cents. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
PDL BioPharma's Proposal to Acquire Neos Therapeutics Expires Today; PDL Urges Neos to Provide Update on Sale Process Wed, 08 Nov 2017 13:00:00 +0000 INCLINE VILLAGE, Nev., Nov. 8, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDLI) reiterated that its proposal to acquire Neos Therapeutics, Inc. (NEOS) for $10.25 per share in cash will expire today at market close. PDL originally made public its proposal to acquire Neos on October 26, 2017 at a premium of approximately 40 percent to the pre-proposal closing price of Neos shares. PDL is confident its proposal represents fair value for the Company and offers certain and compelling value for Neos shareholders.
Neos Therapeutics Reports Third Quarter 2017 Financial Results Wed, 08 Nov 2017 12:00:00 +0000 DALLAS and FORT WORTH, Texas, Nov. 08, 2017-- Neos Therapeutics, Inc., a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release products using its proprietary ...
Neos Therapeutics shares fall after FDA approves new formulation of ADHD drug Fri, 15 Sep 2017 21:10:21 +0000 Shares of Neos Therapeutics Inc. fell more than 5% late Friday after the pharmaceutical company said the U.S. Food and Drug Administration has approved one of its extended-release drugs for Attention Deficit ...
5 of the Best Stocks Under $10 for 2017 Tue, 05 Sep 2017 16:41:04 +0000 Today we've highlighted five stocks that are currently trading for under $10 per share. These stocks are also showing signs for solid growth throughout 2017, and all of them currently hold a Zacks Rank #1 (Strong Buy).
See what the IHS Markit Score report has to say about Zoetis Inc. Thu, 16 Nov 2017 14:44:46 +0000 Short interest is extremely low for ZTS with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ZTS. The net inflows of $3.77 billion over the last one-month into ETFs that hold ZTS are among the lowest of the last year and appear to be slowing.
Zoetis, Inc. : ZTS-US: Dividend Analysis : November 09th, 2017 (record date) : By the numbers : November 10, 2017 Fri, 10 Nov 2017 15:54:54 +0000 Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing Zoetis, Inc. with the following peers – Pfizer Inc., Merck & Co., Inc., Eli Lilly and Company, Parnell Pharmaceuticals Holdings Ltd., Aratana Therapeutics, Inc., Kindred Biosciences, Inc., Sanofi Sponsored ADR, Phibro Animal Health Corporation Class A, Heska Corporation and ImmuCell Corporation (PFE-US, MRK-US, LLY-US, PARNF-US, ... Read more
(Read more...)
Zoetis, Inc. breached its 50 day moving average in a Bullish Manner : ZTS-US : November 8, 2017 Wed, 08 Nov 2017 18:46:21 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Zoetis, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more
(Read more...)
Is It Time To Buy Zoetis Inc (ZTS)? Thu, 02 Nov 2017 22:32:22 +0000 Let’s talk about the popular Zoetis Inc (NYSE:ZTS). The company’s shares received a lot of attention from a substantial price movement on the NYSE in the over the last fewRead More...
ETFs with exposure to Adamas Pharmaceuticals, Inc. : November 24, 2017 Fri, 24 Nov 2017 15:20:35 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Adamas Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ADMS-US. Comparing the performance and risk of Adamas Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
(Read more...)
Adamas to Present at Two Upcoming Investor Conferences Wed, 22 Nov 2017 17:42:07 +0000 EMERYVILLE, Calif., Nov. 22, 2017-- Adamas Pharmaceuticals, Inc. today announced that company management is scheduled to present at two upcoming investor conferences:. Richard A. King, the company’ s Chief ...
Acorda Stock Up Despite Phase III Trial on Tozadenant Stops Tue, 21 Nov 2017 21:29:09 +0000 Acorda (ACOR) decides to suspend the phase III study on tozadenant based on new data obtained from the trial, spotting comprise with patient's safety.
Adamas Announces New Employment Inducement Grant Wed, 08 Nov 2017 21:17:50 +0000 EMERYVILLE, Calif., Nov. 08, 2017-- Adamas Pharmaceuticals, Inc. today announced that the compensation committee of the company’ s board of directors granted five new employees the option to purchase an ...
Adamas Pharmaceuticals, Inc. :ADMS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017 Tue, 07 Nov 2017 13:17:10 +0000 Categories: Yahoo FinanceGet free summary analysis Adamas Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Adamas Pharmaceuticals, Inc. – Catalyst Biosciences, Inc., Merck & Co., Inc., GlaxoSmithKline plc Sponsored ADR and AbbVie, Inc. (CBIO-US, MRK-US, GSK-US and ABBV-US) that have also reported for ... Read more
(Read more...)
Adamas reports 3Q loss Thu, 02 Nov 2017 21:26:36 +0000 On a per-share basis, the Emeryville, California-based company said it had a loss of $1.04. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Adamas Reports Recent Achievements and Third Quarter 2017 Financial Results Thu, 02 Nov 2017 20:01:00 +0000 EMERYVILLE, Calif., Nov. 02, 2017-- Adamas Pharmaceuticals, Inc. today reported recent achievements and financial results for the third quarter ended September 30, 2017.. “We are thrilled that GOCOVRI ...
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.